Legal Opinion
Astrazeneca Pharmaceuticals Lp v. Food and Drug Administration
District Court, District of Columbia
Decided March 23, 2012No. Civil Action No. 2012-0388PublishedCited by 10 opinions
1Opinion of the Court
MEMORANDUM OPINION
COLLEEN KOLLAR-KOTELLY, District Judge.
Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) holds new drug applications for SEROQUEL® (“Seroquel”) and SEROQUEL XR® (“Seroquel XR”), antipsychotic drugs used te treat serious psychological disorders such as schizophrenia. Since AstraZeneca first obtained approval to market these drugs-in the United States from the Food and 1feg Administration (the “FDA”), it hassrcen free to market them without “gengW” competition. Next week, on MondSfMarch 26, 2012, one of AstraZeneql® exclusivity rights, a so-called “pediatiHIxclusivity”…
2Cases cited25 opinions
- Winter v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 2008
- Abbott Laboratories v. GardnerSupreme Court of the United States · 1967
- Califano v. SandersSupreme Court of the United States · 1977
- Duke Power Co. v. Carolina Environmental Study Group, Inc.Supreme Court of the United States · 1978
- Texas v. United StatesSupreme Court of the United States · 1998
20 more not listed; retrieve them via the Exa API.
3Cited by10 opinions
- AstraZeneca Pharmaceuticals LP v. Food & Drug AdministrationCourt of Appeals for the D.C. Circuit · 2013
- Viropharma Incorporated v. HamburgDistrict Court, District of Columbia · 2012
- Astrazeneca Pharmaceuticals Lp v. Food and Drug AdministrationDistrict Court, District of Columbia · 2012
- Veloxis Pharmaceuticals, Inc. v. United States Food and Drug AdministrationDistrict Court, District of Columbia · 2015
- Investment Company Institute v. United States Commodity Futures Trading CommissionDistrict Court, District of Columbia · 2012
5 more not listed; retrieve them via the Exa API.